Abstract
Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bouzubar, N., Walker, K., Griffiths, K. et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59, 943–947 (1989). https://doi.org/10.1038/bjc.1989.200
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.200
This article is cited by
-
Ki-67 Index and Its Correlation with Clinical and Pathological Variables in Breast Cancer
Indian Journal of Surgical Oncology (2023)
-
Characteristics of gut microbiota in patients with gastric cancer by surgery, chemotherapy and lymph node metastasis
Clinical and Translational Oncology (2022)
-
Prediagnostic circulating metabolites in female breast cancer cases with low and high mammographic breast density
Scientific Reports (2021)
-
Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro
Breast Cancer Research and Treatment (2017)
-
Ki67 as a Biomarker of Prognosis and Prediction: Is it Ready for Use in Routine Pathology Practice?
Current Breast Cancer Reports (2014)